Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYADNASDAQ:EVLONYSE:NHWKNASDAQ:VINC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsEVLOEvelo Biosciences$0.05$0.05$0.03▼$13.93$854K2.0446,928 shs32,383 shsNHWKNightHawk Biosciences$0.39$0.26▼$1.16$10.78M0.1997,242 shs173,100 shsVINCVincerx Pharma$5.06-16.5%$3.50$0.61▼$9.37$108.18M1.031.09 million shs601,837 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad Oncology0.00%0.00%0.00%0.00%-31.82%EVLOEvelo Biosciences-13.00%-22.32%-27.50%-27.50%-98.95%NHWKNightHawk Biosciences0.00%0.00%0.00%-15.78%-51.45%VINCVincerx Pharma+18.36%-9.55%+57.81%+482.69%+537.89%Major Elon Musk Crypto Leak Revealed (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ANHWKNightHawk BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AVINCVincerx Pharma0.7004 of 5 stars1.52.00.00.03.12.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad OncologyN/AN/AN/AN/AEVLOEvelo Biosciences2.00HoldN/AN/ANHWKNightHawk Biosciences2.00HoldN/AN/AVINCVincerx Pharma3.00Buy$5.00-1.19% DownsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad OncologyN/AN/AN/AN/A$0.20 per shareN/AEVLOEvelo BiosciencesN/AN/AN/AN/A($0.92) per shareN/ANHWKNightHawk Biosciences$6.38M0.00N/AN/A$2.82 per share0.00VINCVincerx PharmaN/AN/AN/AN/A$2.25 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad Oncology-$43.13MN/A0.00∞N/AN/AN/AN/A3/28/2024 (Estimated)EVLOEvelo Biosciences-$114.53M-$13.29N/A∞N/AN/AN/A-189.58%5/13/2024 (Estimated)NHWKNightHawk Biosciences-$43.44M-$1.99N/AN/AN/A-2,333.27%-91.62%-56.48%3/29/2024 (Estimated)VINCVincerx Pharma-$65.37M-$2.31N/AN/AN/AN/A-160.15%-116.11%5/9/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyad OncologyN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/ANHWKNightHawk BiosciencesN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad Oncology0.341.26N/AEVLOEvelo BiosciencesN/A0.480.48NHWKNightHawk Biosciences0.270.990.99VINCVincerx PharmaN/A2.582.58OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyad OncologyN/AEVLOEvelo Biosciences0.31%NHWKNightHawk Biosciences21.16%VINCVincerx Pharma44.02%Insider OwnershipCompanyInsider OwnershipCYADCelyad Oncology0.94%EVLOEvelo Biosciences1.02%NHWKNightHawk Biosciences15.90%VINCVincerx Pharma20.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableEVLOEvelo Biosciences6618.98 million18.79 millionNo DataNHWKNightHawk Biosciences7726.08 million21.94 millionOptionableVINCVincerx Pharma4121.38 million16.98 millionNot OptionableEVLO, NHWK, CYAD, and VINC HeadlinesSourceHeadlineShort Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Expands By 95.2%marketbeat.com - March 28 at 8:34 AMVincerx Pharma (VINC) Set to Announce Earnings on Tuesdaymarketbeat.com - March 25 at 7:31 AMVincerx Pharma Incedition.cnn.com - March 19 at 11:56 PMWhy Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com - March 12 at 2:55 PMLeerink Partnrs Comments on Vincerx Pharma, Inc.'s Q1 2024 Earnings (NASDAQ:VINC)marketbeat.com - March 9 at 1:39 AMFY2024 EPS Estimates for Vincerx Pharma, Inc. (NASDAQ:VINC) Reduced by Leerink Partnrsmarketbeat.com - March 8 at 7:20 AMBuy Rating Affirmed for Vincerx Pharma Ahead of AACR Presentation: Promising Developments in Oncology Drug Pipelinemarkets.businessinsider.com - March 7 at 2:29 PMVincerx Pharma, Inc. to Post Q1 2024 Earnings of ($0.40) Per Share, Leerink Partnrs Forecasts (NASDAQ:VINC)marketbeat.com - March 7 at 6:40 AMVincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024globenewswire.com - March 5 at 4:31 PMVincerx Pharma, Inc.'s (NASDAQ:VINC) large institutional owners must be happy as stock continues to impress, up 28% over the past weekfinance.yahoo.com - March 5 at 8:12 AMVincerx Pharma Inc Ordinary Shares VINCmorningstar.com - February 22 at 10:08 PMVincerx Pharma Stock (NASDAQ:VINC) Dividends: History, Yield and Datesbenzinga.com - February 22 at 7:06 AMVincerx Pharma stock rises on positive efficacy data from lymphoma therapymsn.com - January 10 at 8:43 AMWhy Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today?msn.com - January 8 at 2:14 PMVincerx Pharma Shares Surge Following Early Results for Relapsed, Refractory Lymphomamarketwatch.com - January 8 at 7:53 AMVincerx Pharma, Inc.: Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphomafinanznachrichten.de - January 8 at 2:53 AMVincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphomafinance.yahoo.com - January 7 at 3:31 PMChecking in on Vincerx Pharma Inc (VINC) after recent insiders movementknoxdaily.com - January 1 at 9:52 PMVincera Pharma: Results Of Operations And Financial Condition, Financial Statements And Exhibitscbonds.com - November 16 at 10:37 AMVincerx Pharma GAAP EPS of -$0.46msn.com - November 14 at 4:52 PMVincerx Pharma, Inc.: Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - November 14 at 8:09 AMThe ‘elegant science’ in achieving the promise of ADCspharmaphorum.com - November 7 at 7:37 PMNew to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Networkfinance.yahoo.com - October 13 at 9:29 AMVincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023finance.yahoo.com - September 19 at 9:09 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCelyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Evelo BiosciencesNASDAQ:EVLOEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.NightHawk BiosciencesNYSE:NHWKNightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.Vincerx PharmaNASDAQ:VINCVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.